SuperworthContineum Therapeutics CTNM
- Market cap
- $312.6M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −17.1%
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | n/a | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $6.5M | $8M | $7.8M+114% | $7.9M−17% | $9.7M+50% | $13M+62% | $13.7M+76% | $14.1M+78% | $11M+13% | $12.8M−2% | $11.6M−15% | $12.7M−10% |
| SG&A | $1.6M | $1.7M | $2.2M+45% | $3M+90% | $3.2M+107% | $4M+142% | $4.4M+104% | $3.8M+26% | $3.9M+21% | $4.4M+8% | $5.3M+20% | $4.7M+23% |
| −$8.1M | −$9.7M | −$9.9M+94% | −$10.9M | −$13M+61% | −$17M+76% | −$18.1M+82% | −$17.9M+64% | −$14.9M+15% | −$17.1M+0% | −$16.9M−7% | −$17.4M−3% | |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$6.4M | −$7.9M | −$8.4M+75% | −$9M | −$10.3M+61% | −$14.6M+84% | n/a | n/a | n/a | n/a | n/a | n/a |
| −$118K | −$161K | $0 | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$6.3M | −$7.8M | −$8.4M+75% | −$9M | −$10.3M+64% | −$14.6M+88% | −$16M+90% | −$16M+78% | −$12.8M+25% | −$15.2M+4% | −$14.5M−10% | −$15.2M−6% |
| −$2.69 | −$0.51 | −$3.55+68% | −$0.39 | −$0.40−85% | −$0.56+10% | −$0.62−83% | −$0.62+59% | n/a | n/a | −$0.39−37% | −$0.40−36% | |
| 2.3M | 2.3M | 2.4M+4% | 23.4M+565% | 25.7M+1007% | 25.8M+1003% | 25.9M+992% | 25.9M+11% | n/a | n/a | 37.3M+44% | 37.5M+45% |
Revenue: Q1 FY23: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q1 FY23 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY23 and Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Contineum Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CTNMContineum Therapeutics | $312.6M | n/m | n/a | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| Peer median | $597.2M | 11.5× | 13.6× | 1.5× | +11% | 11.6% |
More on Contineum Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .